Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed prostate cancer

- Low-risk for progression, as evidenced by all of the following:

- Tumor stage ≤ T2a

- PSA ≤ 10 ng/mL

- Gleason score ≤ 7

- Patients informed of treatment options and has already chosen to undergo active
surveillance

- No decision to stop active surveillance

- No node-positive or metastatic disease

PATIENT CHARACTERISTICS:

- Willing to undergo MRI

- Willing to undergo prostate biopsy

- No contraindications to MRI that include, but not limited to, any of the following:

- Claustrophobia

- Anxiety

- Presence of metal or shrapnel in the body

- Pacemakers

- Old tattoos with metal-based dye material

- No contraindication to prostate biopsy

- No medical conditions, as deemed by the PI or associates, that would prevent or limit
the patient participation on the protocol that include, but not limited to, any of
the following:

- Severe coagulopathy

- History of severe bleeding

- Severe coronary artery disease

- Other comorbid conditions that limit life expectancy to less than 2 years

PRIOR CONCURRENT THERAPY:

- No hormone therapy within the past year

- No prior pelvic radiotherapy

- No prior prostate resection including transurethral resection of prostate

- Concurrent participation in other clinical studies (e.g., vitamin D, selenium)
allowed provided active surveillance is continued